This study was designed to evaluate the prognostic significance of the proliferation marker Mcm2 in a series of diffuse astrocytoma WHO grade II with thorough follow-up, and to compare its expression with histopathological features, mitoses, as well as Ki67/MIB-1 immunostaining. Here, MKI67 is linked to diffuse astrocytoma.